Hi_老虎社区_美港股上老虎

Spng
2021-12-28

China's Kintor says interim analysis of COVID treatment trial misses statistical criteria

BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III cli

China's Kintor says interim analysis of COVID treatment trial misses statistical criteria

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":696864569,"tweetId":"696864569","gmtCreate":1640665183047,"gmtModify":1640665183047,"author":{"id":3576665522010735,"idStr":"3576665522010735","authorId":3576665522010735,"authorIdStr":"3576665522010735","name":"Spng","avatar":"https://static.tigerbbs.com/2e2fe7243dbbe313a5094d73f450b63e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hi</p></body></html>","htmlText":"<html><head></head><body><p>Hi</p></body></html>","text":"Hi","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696864569","repostId":1137683837,"repostType":4,"repost":{"id":"1137683837","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640664098,"share":"https://www.laohu8.com/m/news/1137683837?lang=&edition=full","pubTime":"2021-12-28 12:01","market":"hk","language":"en","title":"China's Kintor says interim analysis of COVID treatment trial misses statistical criteria","url":"https://stock-news.laohu8.com/highlight/detail?id=1137683837","media":"Reuters","summary":"BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III cli","content":"<p>BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.</p>\n<p>\"In a trial that had enrolled 348 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalization was reported,\" a Kintor representative said on Monday.</p>\n<p>The low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.</p>\n<p>Kintor said in a filing on Monday that it will seek consent from authorities, including U.S. Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a COVID-19 vaccination.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Kintor says interim analysis of COVID treatment trial misses statistical criteria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Kintor says interim analysis of COVID treatment trial misses statistical criteria\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-28 12:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.</p>\n<p>\"In a trial that had enrolled 348 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalization was reported,\" a Kintor representative said on Monday.</p>\n<p>The low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.</p>\n<p>Kintor said in a filing on Monday that it will seek consent from authorities, including U.S. Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a COVID-19 vaccination.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137683837","content_text":"BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.\n\"In a trial that had enrolled 348 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalization was reported,\" a Kintor representative said on Monday.\nThe low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.\nKintor said in a filing on Monday that it will seek consent from authorities, including U.S. Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a COVID-19 vaccination.","news_type":1},"isVote":1,"tweetType":1,"viewCount":537,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

China's Kintor says interim analysis of COVID treatment trial misses statistical criteria

评论（1）

热议股票